课题基金 / 基金详情

PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY

PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY
PROCRIT 与安慰剂在接受化疗的贫血乳腺癌患者中的疗效
批准号：
6264606
负责人：
FRANCO MUGGIA
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264606
关键词：
anemia blood transfusion breast neoplasms clinical research drug administration routes drug adverse effect drug screening /evaluation erythropoietin female glycoproteins hemoglobin human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer classification /staging placebos quality of life recombinant proteins

项目摘要

项目成果

FRANCO MUGGIA的其他基金

相似基金

相关文献

中文摘要
翻译
这项随机双盲研究的目的是评价埃博汀α(Procrit)与安慰剂治疗接受化疗的贫血乳腺癌患者的有效性、安全性和临床结果。IV期乳腺癌患者每周将接受4万个单位的皮下注射。将评估生活质量、输血要求、血红蛋白和存活率。
英文摘要
The objective of this randomized, double-blind study is to evaluate the effectiveness, safety, and clinical outcomes of epoetin alpha (Procrit) versus placebo in the treatment of anemic breast cancer patients receiving chemotherapy. Patients with Stage IV breast cancer will receive 40,000 Units subcutaneously every week. Quality of life, transfusion requirements, hemoglobin and survival will be evaluated.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Symposium on Hereditary Breast and Ovarian Cancers: Lessening the Burde
Symposium on Hereditary Breast & Ovarian Cancers: Risk and Challenges
Protocol Specific Research Support
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN
海外基金